Corticosteroid Treatment for Sudden Hearing Loss

A 27-year-old female presenting with acute unilateral tinnitus, ear fullness, and dizziness was diagnosed with a condition that carries a significant risk of progression to a chronic, debilitating disorder. This case of Acute Low-Tone Hearing Loss (ALHL), described by researchers Marsella Lulu Aulia and Gustav Syukrinto, is increasingly understood as a clinical warning sign for cochlear endolymphatic hydrops, a precursor to Menière’s Disease (MD). Their analysis, published with the DOI [10.59141/-.v8i1.503](https://doi.org/10.59141/-.v8i1.503), argues that this diagnosis demands immediate and aggressive treatment to stabilize the inner ear and prevent permanent damage.

Why ALHL is a Critical Warning Sign

The core finding of the research is that ALHL is not an isolated event. It is frequently the clinical manifestation of a cochlear-restricted form of endolymphatic hydrops. This condition involves an abnormal buildup of fluid in the inner ear’s endolymphatic spaces. Because this unstable fluid state is a known precursor to the full spectrum of Menière’s Disease—characterized by vertigo attacks, tinnitus, and fluctuating hearing loss—ALHL is considered highly prone to recurrence and progression. Recognizing ALHL as this specific warning sign shifts the treatment goal from simple symptom relief to actively preventing disease conversion.

Methodology: Building a Treatment Protocol from Evidence

Aulia and Syukrinto conducted a targeted literature review to answer a pressing clinical question: What must clinicians consider when treating ALHL to avoid worsening and achieve complete recovery? They searched databases like PubMed and Google Scholar using the keywords “Acute Low Tone Hearing Loss” AND “Sudden Sensorineural Hearing Loss” AND “Therapy.” This approach synthesized existing clinical evidence and expert recommendations into a coherent management strategy for this specific patient population, moving beyond generic protocols for sudden hearing loss.

Findings: A Multi-Pronged Therapeutic Strategy

The literature review identified several key components for effective ALHL management. These form a sequential and often concurrent treatment plan.

Immediate Anti-Inflammatory Action

First-line therapy centers on the prompt administration of high-dose corticosteroids, typically oral prednisone. This addresses the presumed inflammatory or immune-mediated component of the inner ear injury. The timing is critical; early intervention is linked to better hearing recovery outcomes. This approach is distinct from treatments for conductive hearing loss, which involves mechanical blockages in the outer or middle ear.

Long-Term Fluid Regulation

Since the underlying issue is fluid imbalance (hydrops), long-term management requires “anti-hydrops” agents. These commonly include diuretics like hydrochlorothiazide to reduce systemic and inner ear fluid pressure, and betahistine, a drug believed to improve microcirculation in the inner ear. This phase of treatment aims to create a stable inner ear environment and prevent relapse.

Essential Supportive and Monitoring Measures

The strategy extends beyond medication. Supportive management includes a low-sodium diet to further minimize fluid retention. Most importantly, the researchers stress the necessity of “comprehensive, prolonged audio vestibular surveillance.” This means regular pure-tone audiometry to track hearing thresholds, along with monitoring for vestibular symptoms like dizziness or unsteadiness. This careful observation is vital for detecting early signs of progression to Menière’s Disease.

Practical Implications for Patients and Clinicians

This research provides a clear roadmap. For patients presenting with acute low-tone hearing loss, tinnitus, and aural fullness—even with mild dizziness—clinicians should have a high index of suspicion for endolymphatic hydrops. The case report of the young woman with nausea and vomiting underscores that vestibular symptoms can be present from the outset. The treatment implication is unambiguous: adopt an aggressive, dual-phase approach starting with steroids and transitioning to sustained fluid management, rather than a wait-and-see policy.

This proactive stance is supported by research into other hearing-related neural changes. For instance, understanding the need to stabilize neural pathways aligns with studies on reversing amygdala plasticity in hearing loss, which highlights how auditory disruptions can lead to lasting brain alterations. Furthermore, the emphasis on precise diagnosis and monitoring echoes the value of detailed testing shown in our article on sudden hearing loss prognosis.

For patients, the message is to seek immediate evaluation for these specific symptoms. A standard hearing test can confirm the low-tone loss, prompting a treatment plan designed not just to recover hearing in the short term, but to protect long-term vestibular and auditory function. Complete recovery is the goal, and it depends on recognizing ALHL as the urgent warning sign that it is.